EUVIMEDEUVIMED entdecken
Crossref

Bimiralisib suppresses proliferation and migration of gastric cancer cells via PI3K/mTOR pathway inhibition

You Jin Noh, Hye Eun Jeong, Seo Hyun Cha, Young Ran Shin, Xiaomeng Xie iD, Dong Joon Kim iD

The Korean Journal of Physiology & Pharmacology · 08.07.2026

DOI: 10.4196/kjpp.26.137 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Korean Journal of Physiology & Pharmacology, online erschienen am 08.07.2026. Verfasst von You Jin Noh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, College of Medicine, Dankook University, Cheonan 31116, Korea. Gefördert von: Dankook University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastric cancer remains a leading cause of cancer-related mortality worldwide, underscoring the need for effective targeted therapeutic strategies. The phosphatidylinositol 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) signaling pathway is frequently dysregulated in gastric cancer and represents a promising therapeutic target. However, its clinical applicability remains insufficiently explored. Therefore, this study aimed to identify actionable therapeutic targets and evaluate the potential of a clinically relevant PI3K/mTOR inhibitor, bimiralisib, in gastric cancer. Analysis of The Cancer Genome Atlas dataset revealed elevated expression of PIK3CA and mTOR in gastric cancer tissues. Small-molecule inhibitor screening identified bimiralisib as a potent suppressor of gastric cancer cell viability. Functional assays demonstrated that bimiralisib significantly inhibited cell proliferation, clonogenic growth, spheroid formation, and migration, and induced G1 phase arrest with a reduction in the S phase population. Mechanistically, bimiralisib reduced phosphorylation of AKT and mTOR, confirming effective inhibition of PI3K/mTOR signaling. Consistently, PIK3CA knockdown recapitulated these effects. In addition, bimiralisib treatment was associated with upregulation of E2F4, suggesting a link between pathway inhibition and cell cycle regulation. Collectively, these findings demonstrate that targeting PI3K/mTOR signaling with bimiralisib suppresses gastric cancer cell growth and migration, supporting its potential as a targeted therapeutic strategy.

Schlagwörter

Stichwörter der Autor:innen

PI3K inhibitorStomach neoplasmsTOR Serine-Threonine kinases

Autor:innen und Institutionen

  • Department of Microbiology, College of Medicine, Dankook University, Cheonan 31116, Korea.
  • Cancer Research Center for Precision Medicine (CRCPM), Dankook University, Cheonan 31116, Korea.
  • Medical Research Center, Chest Hospital of Zhengzhou University, Zhengzhou 450008, China.

ORCID-Profile: Xiaomeng Xie, Dong Joon Kim

Förderung

  • Dankook University

Zitieren

APA

Noh, Y. J., Jeong, H. E., Cha, S. H., Shin, Y. R., Xie, X., & Kim, D. J. (2026). Bimiralisib suppresses proliferation and migration of gastric cancer cells via PI3K/mTOR pathway inhibition. The Korean Journal of Physiology & Pharmacology. https://doi.org/10.4196/kjpp.26.137

Vancouver

Noh YJ, Jeong HE, Cha SH, Shin YR, Xie X, Kim DJ. Bimiralisib suppresses proliferation and migration of gastric cancer cells via PI3K/mTOR pathway inhibition. The Korean Journal of Physiology & Pharmacology. 2026. doi:10.4196/kjpp.26.137

BibTeX
@article{Noh2026,
  author = {Noh, You Jin and Jeong, Hye Eun and Cha, Seo Hyun and Shin, Young Ran and Xie, Xiaomeng and Kim, Dong Joon},
  title = {Bimiralisib suppresses proliferation and migration of gastric cancer cells via PI3K/mTOR pathway inhibition},
  journal = {The Korean Journal of Physiology & Pharmacology},
  year = {2026},
  doi = {10.4196/kjpp.26.137}
}
Kostenlos starten →